AJANTPHARM2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2020-04-01 2021-03-31 2021-01-23 INR Crores Third quarter Single segment PHARMACEUTICAL 2020-10-01 2020-12-31 Unaudited Standalone 7331600000.00 29000000.00 7360600000.00 1916400000.00 270200000.00 -154700000.00 1226900000.00 21700000.00 279500000.00 1617200000.00 5177200000.00 2183400000.00 0.00 2183400000.00 359100000.00 24800000.00 383900000.00 0.00 1799500000.00 0.00 0.00 0.00 0.00 1799500000.00 -6100000.00 1793400000.00 1793400000.00 0.00 173900000.00 2 20.80 20.80 0.00 0.00 20.80 20.80 1. The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 2 February 2021. n2. Statutory Auditors have expressed an unqualified review opinion for quarter and nine month ended 31 December 2020. n4. During the quarter 5,500 equity shares (previous year Nil) of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by Rs. 11,000 (previous year Rs. Nil) and securities premium account by Rs. 0.58 crores (previous year Rs. Nil). n5. Exceptional item in the quarter and nine months ended 31 December 2019 and year ended 31 March 2020 represents loss due to a fire and other events at Guwahati plant net of minimum insurance claim receivable. The claim has been settled and there is no further loss on this account. n6. During the quarter, Company had bought back its 7,35,000 equity shares, being 0.84% of the total paid up equity share capital at Rs. 1,850 per equity share for an aggregate amount of Rs. 135.98 crores and extinguished those shares on 30 December 2020. n7. The Company continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Company has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Company will continue to closely monitor future economic conditions to ensure business continuity. n8. The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals . n9. The Financial Results are available for investors at on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. Single segment 2020-04-01 2020-12-31 Unaudited Standalone 19705200000.00 1022400000.00 20727600000.00 5325600000.00 781400000.00 -823800000.00 3646700000.00 47200000.00 820100000.00 4077000000.00 13874200000.00 6853400000.00 0.00 6853400000.00 1481300000.00 163500000.00 1644800000.00 0.00 5208600000.00 0.00 0.00 0.00 0.00 5208600000.00 -18100000.00 5190500000.00 5190500000.00 0.00 173900000.00 2 60.20 60.19 0.00 0.00 60.20 60.19 Other Expenses 1617200000.00 Other Expenses 4077000000.00